

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

## **INFORMATION DISCLOSURE STATEMENT**

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The citation of information on the attached form PTO/SB/08A (1449/PTO), "Information Disclosure Statement by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98.

The citation of this information does not constitute an admission that any of the materials are available as a reference or of priority, or a waiver of any right applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Pursuant to 37 C.F.R. § 1.97(b)(3), Applicants have not submitted herewith a filing fee because this information is being submitted prior to the mailing of the first Office action on the

EXPRESS MAIL No.: EL 973738905 US


July 31, 2006

Information Disclosure Statement  
Serial No. To be Assigned

10/537995

merits in this case. However, if any fees are associated with this filing, the Patent Office is hereby authorized to charge such fees to Deposit Account 19-5029.

Respectfully submitted,



William L. Warren  
Reg. No. 36,714

SUTHERLAND ASBILL & BRENNAN LLP  
999 Peachtree Street, NE  
Atlanta, Georgia 30309-3996  
Telephone: (404) 853-8000  
Facsimile: (404) 853-8806  
Attorney Docket: 25991-0002

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

10/587995

Substitute for form 1449/PTO					
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)					
Sheet	1	of	1	Attorney Docket Number	25991-0002

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1	US-			
	A2	US-			
	A3	US-			
	A4	US-			
	A5	US			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Patent Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>2</sup> (if known)				
	B1	EP 1074617	02-07-2001	Helix Res. Inst.		
	B2	WO 02/070539	09-12-2002	Hyseq Inc.		
	B3	WO 03/083047	10-09-2003	Exelixis Inc.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the articles (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Database EMBL [Online] Mus musculus axotrophin mRNA, complete cds. (1999-06-15), HAENDEL et al., "Insertional mutagenesis of a novel gene, axotrophin, causes callosal RT agenesis and neural degeneration" XP002338547, Database accession no. AF155739 abstract	
	C2	Database EMBL [Online] Hypothetical protein FLJ12911 (Axotrophin) (1999-03-01), XP002338548, Database accession no. Q9H992, Homo sapiens abstract	
	C3	Database EMBL [Online] Axotrophin March 7 protein) (1999-11-01), XP002338549, Database accession no. Q9WV66, Mus musculus abstract	
	C4	RAMALHO-SANTOS M. et al., "Stemness: transcriptional profiling of embryonic and adult stem cells", Science, American Association for the Advancement of Science, US, vol. 298, no. 5593, (2002-10-18), pages 597-600, XP002327804, ISSN: 0036-8075	
	C5	Database Geneseq [Online], (2001-06-26), "Human protein sequence SEQ ID NO:17375", XP002338550, retrieved from EBI accession no. GSN: AAB95234, Database accession no. AAB95234	
	C6	Database Geneseq [Online] (2004-02-12), "Human MP53 protein sequence SEQ ID NO:59", XP002338551, retrieved from EBI accession no. GSN: ADF69089, Database accession no. ADF69089 abstract	
	C7	Database Geneseq [Online] (2003-01-20), "Human polypeptide SEQ ID NO 1612", XP002338552, retrieved from EBI accession no. GSN: ABP69565, Database accession no. ABP69565 abstract	
	C8	YAMASAKI SHINSUKE et al., "Characterization of a gene expressed in layer 5 of the neocortex", Neuroscience Research Supplement, No. 26, 2002, page S109, XP008050575 & 25th Annual Meeting of the Japan Neuroscience Society, Tokyo, Japan, July 7, 2002-July 9, 2003, ISSN: 0921-8696 abstract	
	C9	METCALFE S M et al., "Transplantation tolerance: gene expression profiles comparing allotolerance vs. allorejection", International Immunopharmacology, Elsevier, Amsterdam, NL, vol. 5, no. 1, (2005-01), pages 33-39, XP004678650, ISSN: 1567-5769 whole document	
	C10	METCALFE S M et al., "Leukaemia inhibitory factor (LIF) is functionally linked to axotrophin and both LIF and axotrophin are linked to regulatory immune tolerance" FEBS Letters, Elsevier Science Publishers, Amsterdam, NL, vol. 579, no. 3, (2005-01-31), pages 609-614, XP004725165, ISSN: 0014-5793 whole document	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.